Epithelial ovarian cancer.
Stephanie Lheureux, Charlie Gourley, Ignace Vergote...
https://pubmed.ncbi.nlm.nih.gov/30910306Actively Recruiting
Age: 18Years +
FEMALE
ID06564428
A Cohort Study of Hereditary Ovarian Cancer Risk Prediction Models and Pathogenesis Exploration
Led by Peking University Third Hospital · Updated on 2025-06-18
1000
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are conducting a multicenter observational study to understand hereditary ovarian cancer among Chinese patients. The study aims to describe the clinical and genetic features of hereditary ovarian cancer and establish a risk prediction model to estimate cancer risk in first-degree relatives of mutation carriers. It also seeks to identify new tumor-causing mutations in families with hereditary ovarian cancer where known genetic causes are not found. Participants include patients diagnosed with epithelial ovarian cancer, divided into two groups: those with suspected gene mutations or a family history of cancer, and those without these factors. The study will follow these groups from 2024 to 2026 to analyze clinical, pathological, and genetic information. Through genetic sequencing and family history, the research team will explore new genetic mechanisms and verify the risk prediction model. Participants will undergo genetic testing and clinical evaluations over the study period from 2024 to 2026. Researchers will collect data on tumor features, gene mutations, and family histories. The primary outcome is to describe clinicopathological and genetic characteristics of hereditary ovarian cancer. Secondary outcomes include monitoring new ovarian cancer cases in first-degree relatives. The study aims to guide personalized diagnosis, treatment, and preventive interventions for high-risk families.
CONDITIONS
Brief Title
A Cohort Study of Hereditary Ovarian Cancer Risk Prediction Models and Pathogenesis Exploration
Who Can Participate
Age: 18Years +
FEMALE
Eligibility Criteria
You may qualify if you...
- Diagnosed with epithelial ovarian cancer
- At least 18 years old
- Clear pathological diagnosis of ovarian cancer
- Genetic test shows germ line pathogenic or suspected pathogenic mutations as per American ACMG standards
You will not qualify if you...
- Diagnosed with non-epithelial ovarian cancer confirmed by pathology
- Has not undergone genetic testing for ovarian cancer mutations
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
1
2
3
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Monitoring
Duration - Up to 3 years
Participants are observed to describe the clinicopathological and genetic mutation characteristics of hereditary ovarian cancer and to follow up on family history and gene mutations.
Periodic visits for follow-up assessments over the study period
Trial Site Locations
Total: 1 location
1
Peking University Third Hospital
Beijing, Beijing Municipality, China, 100000
Actively Recruiting
Loading map...
Research Team
Y
Yuan Li, Doctor
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Published Research Related To This Trial
Hereditary breast and ovarian cancer: new genes in confined pathways.
Finn Cilius Nielsen, Thomas van Overeem Hansen, Claus Storgaard Sørensen
https://pubmed.ncbi.nlm.nih.gov/27515922Hereditary breast and ovarian cancer (HBOC): review of its molecular characteristics, screening, treatment, and prognosis.
Reiko Yoshida
https://pubmed.ncbi.nlm.nih.gov/32862296Milestones of Lynch syndrome: 1895-2015.
Henry T Lynch, Carrie L Snyder, Trudy G Shaw...
https://pubmed.ncbi.nlm.nih.gov/25673086Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: US Preventive Services Task Force Recommendation Statement.
US Preventive Services Task Force, Douglas K Owens, Karina W Davidson...
https://pubmed.ncbi.nlm.nih.gov/31429903A preliminary validation of a family history assessment form to select women at risk for breast or ovarian cancer for referral to a genetics center.
C A Gilpin, N Carson, A G Hunter
https://pubmed.ncbi.nlm.nih.gov/11076055A new scoring system for the chances of identifying a BRCA1/2 mutation outperforms existing models including BRCAPRO.
D G R Evans, D M Eccles, N Rahman...
https://pubmed.ncbi.nlm.nih.gov/15173236Evaluation of a breast/ovarian cancer genetics referral screening tool in a mammography population.
Cecelia A Bellcross, Amy A Lemke, Laura S Pape...
https://pubmed.ncbi.nlm.nih.gov/19752737Validation of a tool for identifying women at high risk for hereditary breast cancer in population-based screening.
Kent F Hoskins, Alice Zwaagstra, Michael Ranz
https://pubmed.ncbi.nlm.nih.gov/16967460Development and validation of a simple questionnaire for the identification of hereditary breast cancer in primary care.
Patricia Ashton-Prolla, Juliana Giacomazzi, Aishameriane V Schmidt...
https://pubmed.ncbi.nlm.nih.gov/19682358